RxSight (RXST) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

RxSight

NasdaqGM•Healthcare•Medical Devices

$6.02+0.06(0.01%)Market closed

Market Cap

$215.75M

P/S

1.7x

P/B

0.8x

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

How this company scores

WeakMetricSide Score: 20/100

Grade capped at D — Interest coverage below 1× (-4592.8x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (7/25); weakest: Cash & Earnings Quality (4/25).

Profitability5/25

Growth4/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality4/25

Strengths

Net cash positionImproving margins

Grade capped at D

Interest coverage below 1× (-4592.8x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.7x5y range 1.7x – 20.1x

Currently below its 18-quarter median.

P/B · 0.8x5y range 0.8x – 11.3x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $215.75M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $127.58M
Q. Revenue: $33.74M
TTM EBITDA: $-51.58M
TTM Op. Income: $-55.11M
Q. Op. Income: $-13.77M
TTM Net Income: $-46.95M
Q. Net Income: $-12.10M
EPS: $-0.29
Shares Out.: $41.49M

$127.58M in TTM revenue declined 13.2% YoY, reaching $33.74M last quarter. TTM EBITDA of $-51.58M and TTM operating income of $-55.11M show growth is flowing through to the bottom line. However, net income is negative at $46.95M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 13% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 76.7%
EBITDA Margin: -37.9%
Op. Margin: -40.8%
Net Margin: -35.9%

Op. margin of -40.8% is up 0.8% YoY — cost efficiency is improving. Net margin at -35.9% and gross margin of 76.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 2% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.7x
P/B Ratio: 0.8x

P/S of 1.7x and P/B of 0.8x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $352.70M
Cash: $13.35M
Long-Term Debt: N/A
Book Value: $263.34M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-9.54M
TTM Free Cash Flow: $-27.16M
FCF Margin: -21.3%
FCF / Net Income: 0.6

TTM FCF of $-27.16M on $-9.54M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.